CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Citraconate preserves T cell stemness and antitumor immunity.
Citraconate preserves T cell stemness and antitumor immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤微环境中的代谢扰动严重损害CD8 T细胞的干样特性和效应功能。解析维持T细胞干性的代谢回路对于重新激活TIL(肿瘤浸润淋巴细胞)和增强免疫治疗疗效至关重要。在此,我们鉴定出柠康酸——衣康酸的一种异构体——是在经历慢性抗原刺激或缺氧条件的CD8 T细胞中显著耗竭的代谢物。补充柠康酸可维持干样特征、减轻铁死亡并增强T细胞介导的抗肿瘤免疫。在机制上,柠康酸通过抑制磷酸二酯酶1A/C(PDE1A/C)表达和维持线粒体完整性来维持细胞内环磷酸腺苷(cAMP)浓度,从而激活蛋白激酶A(PKA)信号通路。该激活在转录水平抑制花生四烯酸-5-脂氧合酶(ALOX5),进而减少花生四烯酸过氧化。在临床上,ALOX5或PDE1A表达降低与T细胞耗竭减少及对免疫检查点阻断(ICB)治疗反应改善相关。我们的发现揭示了柠康酸介导的PDE1-cAMP-ALOX5轴作为增强癌症免疫治疗的潜在治疗靶点。
Metabolic perturbations in the tumor microenvironment profoundly compromise the stemlike properties and effector functions of CD8 T cells. Deciphering the metabolic circuitry that sustains T cell stemness is critical for reinvigorating tumor-infiltrating lymphocytes and augmenting immunotherapeutic efficacy.
Here, we identify citraconate, an itaconate isomer, as a metabolite markedly depleted in CD8 T cells subjected to chronic antigen stimulation or hypoxic conditions. Citraconate supplementation preserves stemlike characteristics, attenuates ferroptosis, and potentiates T cell-mediated antitumor immunity.
Mechanistically, citraconate maintains intracellular cyclic adenosine monophosphate (cAMP) concentrations by suppressing phosphodiesterase1A/C (PDE1A/C) expression and preserving mitochondrial integrity, thereby activating protein kinase A (PKA) signaling. This activation transcriptionally represses arachidonate-5-lipoxygenase (ALOX5), consequently reducing arachidonic acid peroxidation. Clinically, diminished ALOX5 or PDE1A expression correlates with reduced T cell exhaustion and improved responses to immune checkpoint blockade (ICB) therapy.
Our findings reveal the citraconate-mediated PDE1-cAMP-ALOX5 axis as a potential therapeutic target for enhancing cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。